STC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway
Open Access
- 17 March 2026
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Background While growing evidence highlights the significance of metabolic reprogramming in colorectal cancer (CRC), the exact mechanisms behind these changes remain unclear. This study sought to identify key metabolic regulators and clarify their downstream pathways in CRC progression. Methods Three independent CRC datasets were subjected to differential expression analysis and lactylation-related gene screening, resulting in candidate genes, among which the STC2 gene was prioritized. STC2 expression was first assessed in HIEC-6, Caco-2, LoVo, SW480, and HCT116 cells. STC2 knockdown and overexpression models were established in HCT116 cells to examine their effects on proliferation, migration, invasion, and apoptosis. Lactate production and glucose uptake tests, Western blot, chromatin immunoprecipitation (ChIP), and Quantitative real-time polymerase chain reaction (qRT-PCR) were utilized to delineate the molecular mechanisms. A xenograft mouse model was applied to validate in vivo effects. Results STC2 levels in CRC cells are significantly higher than in normal intestinal cells. STC2 knockdown inhibits cell growth and glycolysis, but its overexpression significantly enhances these activities. Mechanistically, STC2 enhanced c-Myc activity through the PI3K/AKT/mTOR pathway, which upregulated GLUT1 and LDHA to maintain glycolytic flux. ChIP analysis showed that c-Myc occupancy on the GLUT1 and LDHA promoters was increased under STC2 overexpression, whereas binding was reduced upon STC2 silencing. In vivo, STC2 overexpression accelerated tumor growth and enhanced glycolysis in a xenograft mouse model. Conclusion These findings highlight STC2 as a key regulator of CRC progression, which regulates c-Myc-driven glycolysis through the PI3K/AKT/mTOR pathway. Targeting STC2 or its downstream metabolic effectors may provide new therapeutic strategies for CRC management.Keywords
Funding Information
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
- the Minhang District Medical Education and Research Collaborative Health Service System High-level Specialist Key physician Training project ((2024-2027) (2024MZYS16))
This publication has 42 references indexed in Scilit:
- N-myc downstream-regulated gene 2, co-regulated by transcription factors c-MYC and SP1, reduces cell proliferation by interacting with mTOR in GBMBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- Assessing the Colorectal Cancer Landscape: A Comprehensive Exploration of Future Trends in 216 Countries and Territories from 2021 to 2040Journal of Epidemiology and Global Health, 2025
- Melatonin effect on breast and ovarian cancers by targeting the PI3K/Akt/mTOR pathwayIUBMB Life, 2024
- Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapyActa Pharmacologica Sinica, 2024
- CircVMP1 promotes glycolysis and disease progression by upregulating HKDC1 in colorectal cancerEnvironmental Toxicology, 2023
- Development of lactate‐related gene signature and prediction of overall survival and chemosensitivity in patients with colorectal cancerCancer Medicine, 2023
- MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastomaNon-coding RNA Research, 2022
- Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based studyThe Lancet Oncology, 2021
- The novel prognostic risk factor STC2 can regulate the occurrence and progression of osteosarcoma via the glycolytic pathwayBiochemical and Biophysical Research Communications, 2021
- Pseudouridylate Synthase 7 Promotes Cell Proliferation and Invasion in Colon Cancer Through Activating PI3K/AKT/mTOR Signaling PathwayDigestive Diseases and Sciences, 2021